Mild Nonproliferative Diabetic Retinopathy
3
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Phacoemulsification
Related Conditions
Often studied with 7 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
33%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy
Biomarkers of Diabetic Retinopathy Progression
Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography
Research Network
Common Treatments
- Phacoemulsification1
- Ranibizumab1
Active Sponsors
- Association for Innovation and Biomedical Research on Light and Image1
- Retina Institute of Hawaii1
- Ruijin Hospital1
Top Investigators
Association for Innovation and Biomedical Research on Light and Image
Department of Ophthalmology, Ruijin Hospital north, Affiliated Medical School, Shanghai Jiaotong University
Retina Institute of Hawaii
Related Conditions
- Severe Nonproliferative Diabetic Retinopathy1
- Type 2 Diabetes Mellitus1
- Diabetic Macular Edema1
- Cataract Diabetic1
- Diabetic Retinopathy1